Open AccessGastric neuroendocrine tumor: A practical literature review
Author(s) -
Gabriel Antônio Roberto,
Carolina Magalhães Britto Rodrigues,
Renata D’Alpino Peixoto,
Riad Naim Younes
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i8.850
Subject(s) - medicine , neuroendocrine tumors , enterochromaffin cell , somatostatin , gastroenterology , gastrectomy , enterochromaffin like cell , gastrinoma , chemotherapy , incidence (geometry) , gastric tumor , gastrin , octreotide , stomach , cancer , gastric mucosa , physics , receptor , secretion , serotonin , optics
Gastric neuroendocrine tumors are gastric neoplasms originating from enterochromaffin type cells and are inserted in a larger group, named gastroenteropancreatic neuroendocrine tumors. They are considered rare and variable in terms of their clinical, morphological and functional characteristics and may be indolent or aggressive. They are classified into types I, II and III, according to their pathophysiology, behavior and treatment. Their diagnosis occurs, in most cases, incidentally during upper digestive endoscopies, presenting as simple gastric polyps. Most cases (type I and type II) are related to hypergastrinemia, can be multiple and are treated by endoscopic resection, whenever possible. The use of somatostatin analogs for tumor control may be one of the options for therapy, in addition to total or subtotal gastrectomy for selected cases. Adjuvant chemotherapy is only reserved for poorly differentiated neuroendocrine carcinomas. Although rare, gastric neuroendocrine tumors have an increasing incidence over the years, therefore deserving more comprehensive studies on its adequate treatment. The present study reviews and updates management recommendations for gastric neuroendocrine tumors.